SCHLECHTWEG v. CELULARITY, INC.

CourtDistrict Court, D. New Jersey
DecidedSeptember 23, 2022
Docket2:22-cv-01356
StatusUnknown

This text of SCHLECHTWEG v. CELULARITY, INC. (SCHLECHTWEG v. CELULARITY, INC.) is published on Counsel Stack Legal Research, covering District Court, D. New Jersey primary law. Counsel Stack provides free access to over 12 million legal documents including statutes, case law, regulations, and constitutions.

Bluebook
SCHLECHTWEG v. CELULARITY, INC., (D.N.J. 2022).

Opinion

Not for Publication

UNITED STATES DISTRICT COURT DISTRICT OF NEW JERSEY

JOHN SCHLECHTWEG,

Plaintiff, Civil Action No. 22-CV-01356 v. (JMV)(ESK)

CELULARITY, INC., OPINION

Defendant.

John Michael Vazquez, U.S.D.J. This case arises out of the employer-employee relationship between the parties and an alleged verbal contract changing the employee’s role and compensation. Plaintiff John Schlechtweg sued Celularity, Inc. (“Celularity”) for breach of contract and unjust enrichment in connection with his work on an asset sale on behalf of Celularity. Currently pending before the Court is Defendant’s motion to dismiss Plaintiff’s Amended Complaint. D.E. 45. The Court reviewed the parties’ submissions1 and decided the motion without oral argument pursuant to Fed. R. Civ. P. 78(b) and L. Civ. R. 78.1(b). For the following reasons, Defendant’s motion is GRANTED in part and DENIED in part.

1 Defendant’s motion to dismiss, D.E. 45 (“Br.”); Plaintiff’s opposition, D.E. 47 (“Opp.”); and Defendant’s reply in further support of their motion to dismiss, D.E. 52 (“Reply”). I. BACKGROUND2

Plaintiff began working for Celularity as its Director of Strategic Accounts in Spring 2018. D.E. 16 (“Am. Compl.”) ¶ 10. In this role, Plaintiff managed a sales team tasked with selling Celularity’s wound care products and Biologics portfolio to hospitals, physician practices, and governmental entities. Id. ¶ 10. Before starting, Plaintiff and Defendant signed a document dated March 31, 2018 which described itself as an “offer of employment,” (the “Employment Agreement”) and set forth Plaintiff’s role, compensation, benefits, vacation, and other terms. D.E. 45-3, Ex. A. The Employment Agreement includes the following provision: This letter agreement, and the enclosed Proprietary Information and Inventions Agreement, constitute the complete agreement between you and Celularity, and supersede any prior agreements, representations or understandings between you and Celularity. This letter agreement may not be amended or modified except by an express written agreement signed by both you and an authorized officer of Celularity. Id. In 2019, Celularity’s CEO, Dr. Robert Hariri, and President, Dr. Steve Brigido, decided to pursue a sale or lease of the company’s wound care assets. Am. Compl. ¶ 21. This step was part of a larger strategy to enhance Celularity’s marketability as a potential merger partner. Id. ¶¶ 22- 23. Dr. Brigido approached Plaintiff on or about September 15, 2019 and asked Plaintiff to change his primary job function to work on the sale or lease of Celularity’s wound care assets. Id. ¶ 24. Dr. Brigido stated that Plaintiff would be “handsomely rewarded” if he was able to sell or lease

2 The Factual Background is taken from Plaintiff’s Amended Complaint. The Court also considered the Employment Agreement (defined below) because it is integral to the pleading and is directly referenced in the Amended Complaint. See U.S. Express Lines Ltd. v. Higgins, 281 F.3d 383, 388 (3d Cir. 2002) (explaining that when deciding a motion to dismiss under Rule 12(b)(6), a court may rely on “a document integral to or explicitly relied upon in the complaint” (emphasis in original) (citation omitted)). the wound care assets. Id. Plaintiff contends that his acceptance of this offer was a “Verbal Contract.” Plaintiff was concerned that this change of role would prevent him from earning sales incentive compensation, which was tied to his team’s sale of products to hospitals, medical practices, and governmental agencies. Id. ¶ 26. Despite these reservations, and in reliance on Dr.

Brigido’s promise of a “handsome[] reward[],” Plaintiff decided to accept the new role and began working towards the sale of the wound care assets. Id. ¶¶ 27-29. Plaintiff ceased his prior function of selling products to hospitals, medical practices, and governmental agencies, which resulted in a reduction of his overall compensation. Id. ¶ 35. As a result of Plaintiff’s efforts, an agreement to purchase and license the wound care assets was successfully negotiated. Id. ¶ 36. The sale closed on or about August 10, 2020 for a purchase price of $24 million. Id. ¶ 38. The sale also created an expectation of significant licensing royalties, and “improved Celularity’s value as a merger partner.” Id. ¶¶ 38, 40. As a result of this improved value, Celularity’s overall strategy was realized, and a merger was announced on

January 8, 2021. Id. ¶ 40. Immediately after the asset sale, Plaintiff asked Dr. Brigido when he would receive compensation for his role in procuring the sale. Id. ¶ 41. Dr. Brigido stated that “he and Dr. Hariri were working on the compensation package,” and later told Plaintiff “You have my word hang tight, working with Bob [Hariri].” Id. ¶ 41. Plaintiff asked Dr. Brigido numerous times about his compensation in connection with the asset sale, and Dr. Brigido consistently responded that he was “trying to get the payment for Mr. Schlechtweg.” Id. ¶ 42. On or about December 4, 2020, Dr. Brigido stated that a decision on Plaintiff’s compensation was “with comp committee.” Id. ¶ 44. Celularity never paid Plaintiff for his work in connection with the asset sale. Id. ¶ 46. Plaintiff filed the Amended Complaint in the United States District Court for the District of Connecticut on August 18, 2021. The Amended Complaint alleges breach of contract and, in the alternative, unjust enrichment. On February 23, 2022, the Connecticut court granted Defendant’s motion to dismiss for lack of personal jurisdiction and transferred the action to this District. D.E. 33. The current motion followed.3

II. STANDARD OF REVIEW

Defendant moves to dismiss the Amended Complaint for failure to state a claim upon which relief can be granted. Fed. R. Civ. P. 12(b)(6). To withstand a motion to dismiss under Rule 12(b)(6), a plaintiff must allege “enough facts to state a claim to relief that is plausible on its face.” Bell Atl. Corp. v. Twombly, 550 U.S. 544, 570 (2007). A complaint is plausible on its face when there is enough factual content “that allows the court to draw the reasonable inference that the defendant is liable for the misconduct alleged.” Ashcroft v. Iqbal, 556 U.S. 662, 678 (2009). Although the plausibility standard “does not impose a probability requirement, it does require a pleading to show more than a sheer possibility that a defendant has acted unlawfully.” Connelly v. Lane Constr. Corp., 809 F.3d 780, 786 (3d Cir. 2016) (internal quotation marks and citations omitted). As a result, a plaintiff must “allege sufficient facts to raise a reasonable expectation that discovery will uncover proof of [his] claims.” Id. at 789. In evaluating the sufficiency of a complaint, a district court must accept all well-pleaded factual allegations in the complaint as true and draw all reasonable inferences in favor of the plaintiff. Phillips v. County of Allegheny, 515 F.3d 224, 231 (3d Cir. 2008). A court, however, is “not compelled to accept unwarranted inferences, unsupported conclusions or legal conclusions

3 While Plaintiff did not timely file its opposition brief initially, the Court granted Plaintiff’s request for an extension of time. D.E. 51. disguised as factual allegations.” Baraka v.

Free access — add to your briefcase to read the full text and ask questions with AI

Related

Cooper v. Samsung Electronics America, Inc.
374 F. App'x 250 (Third Circuit, 2010)
Bell Atlantic Corp. v. Twombly
550 U.S. 544 (Supreme Court, 2007)
Ashcroft v. Iqbal
556 U.S. 662 (Supreme Court, 2009)
Dan Lind v. Schenley Industries Inc
278 F.2d 79 (Third Circuit, 1960)
Francis Van Orman, on His Own Behalf and on Behalf of a Class of All Participants, Continuing Former Employees, Pensioners, Beneficiaries and Contingent Survivors, as Such Persons Are Defined in the Revised Retirement Plan of the American Insurance Company, American Automobile Insurance Company and Associated Indemnity Corporation ("Tarp") v. The American Insurance Company, the American Automobile Insurance Company, the Associated Indemnity Corporation, Fireman's Fund Insurance Company, Fireman's Fund American Life Insurance Company, Tarp, and Fireman's Fund American Retirement Plan("farp"), Robert P. J. Cooney and Jack B. McCowan Nellie Taylor, Andrew Marsh, Ulice M. Hoover, Peggy Laing, Richard Shultis and Waldermar Ogren, on Their Own Behalf and on Behalf of All Participants and Beneficiaries Similarly Situated v. The American Insurance Company, the American Automobile Insurance Company, the Associated Indemnity Corporation, Fireman's Fund Insurance Company, Fireman's Fund American Life Insurance Company, Robert P. J. Cooney, Jack B. McCowan and Tarp, Francis Van Orman, on His Own Behalf and on Behalf of All Participants and Beneficiaries Similarly Situated, and Ulice M. Hoover, Nellie Taylor, Peggy Laing, Andrew Marsh, Richard Shultis, and Waldemar H. Ogren, on Behalf of Those and All Other Persons Similarly Situated, in No. 81-2784. The American Insurance Company, the American Automobile Insurance Company, Theassociated Indemnity Corporation, Fireman's Fund Insurance Company,fireman's Fund American Life Insurance Company, Tarp, and Farp, Robert P. j.cooney and Jack b.mccowan and the American Insurance Company, the American Automobile Insurance Company, the Associated Indemnity Corporation, Fireman's Fund Insurance Company, Fireman's Fund American Life Insurance Company, Robert P. J. Cooney, Jack B. McCowan and Tarp, in No. 81-2785 the American Insurance Company, American Automobile Insurance Company, Associated Indemnity Corporation, Fireman's Fund Insurance Company, the Revised Retirement Plan of the American Insurance Company, Fireman's Fund American Retirement Plan, Robert P. J. Cooney and Jack B. McCowan and Fireman's Fund Insurance Company, American Insurance Company, American Automobile Insurance Company, Associated Indemnity Corporation, the Revised Retirement Plan of the American Insurance Company, Associated Indemnity Corporation, Fireman's Fund American Life Insurance Company, Robert P. J. Cooney, and Jack B. McCowan in No. 81-2786
680 F.2d 301 (Third Circuit, 1982)
U.S. Express Lines, Ltd. v. Higgins
281 F.3d 383 (Third Circuit, 2002)
Phillips v. County of Allegheny
515 F.3d 224 (Third Circuit, 2008)
McGrath v. Poppleton
550 F. Supp. 2d 564 (D. New Jersey, 2008)
Inter-City Tire & Auto Center, Inc. v. Uniroyal, Inc.
701 F. Supp. 1120 (D. New Jersey, 1988)
Weichert Co. Realtors v. Ryan
608 A.2d 280 (Supreme Court of New Jersey, 1992)
Duffy v. Charles Schwab & Co., Inc.
123 F. Supp. 2d 802 (D. New Jersey, 2000)
Hassler v. Sovereign Bank
644 F. Supp. 2d 509 (D. New Jersey, 2009)
MDC Investment Property, L.L.C. v. Marando
44 F. Supp. 2d 693 (D. New Jersey, 1999)
Baraka v. McGreevey
481 F.3d 187 (Third Circuit, 2007)
Sandra Connelly v. Lane Construction Corp
809 F.3d 780 (Third Circuit, 2016)
Globe Motor Company v. Ilya Igdalev(074996)
139 A.3d 57 (Supreme Court of New Jersey, 2016)

Cite This Page — Counsel Stack

Bluebook (online)
SCHLECHTWEG v. CELULARITY, INC., Counsel Stack Legal Research, https://law.counselstack.com/opinion/schlechtweg-v-celularity-inc-njd-2022.